Fierce Pharma features a discussion with CEO, Bobby Sheng in an article entitled "After Bora's biologics debut, CEO outlines quest to join ranks of top CDMOs". Published on November 10, 2022Thank you Fierce Pharma and author Fraiser Kansteiner Bora's focus on customer partnership is key to Bora's acquisition strategy. Bora's recent addition of biologics offerings with acquisition of Eden...
News and Events
Bora expands its CMDO capabilities as it makes landmark acquisition of TWi Pharmaceuticals
Bora establishes a lead position in Taiwan's CDMO sector TAIWAN - Fast-growing contract development and manufacturing organization (CDMO), Bora Pharmaceuticals, has completed the acquisition of TWi Pharmaceutical Co.Ltd, a technology-based company specializing in development and commercialization of niche generic drugs. Acquiring TWi Pharmaceuticals adds two manufacturing facilities and will...
Bora Pharmaceuticals acquires Eden Biologics CDMO Assets
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market Taiwan-based premier international contract development and manufacturing organization (CDMO) Bora Pharmaceuticals recently announced the establishment of Bora Biologics Co., Ltd., a CDMO platform for biologics. Besides Bora, investors into the new entity include Taishin...
KYOWA Pharmaceutical Industry Co. Ltd. Partners with Bora Pharmaceuticals to manufacture generic product for filing in Japan
KYOWA Pharmaceutical Industry Co. Ltd., a premier Japanese pharmaceutical company, has contracted with Bora Pharmaceutical Laboratories Inc. (Zhunan), a division of Bora Pharmaceuticals for the manufacturing of generic product for filing in Japan. KYOWA will be the first Japanese client for Bora’s Zhunan manufacturing site which is already USFDA, MHRA, and TFDA approved. This project will...